Search Within

Mikhail Roshal

  1. "Biostatistics Service"
Formats
  1. Journal Article (27)
  2. Meeting Abstract (22)
  3. Research Letter (3)
  4. Correspondence (1)
Groups
  1. Biostatistics Service (53)
  2. Department of Pathology and Laboratory Medicine (53)
  3. Epidemiology and Biostatistics (53)
  4. Center for Hematologic Malignancies (52)
  5. Department of Medicine (51)
  6. Hematologic Malignancies, Division of (51)

More Groups

People
  1. Sean Devlin (31)
  2. Sergio Giralt (30)
  3. Maria Arcila (24)
  4. Andriy Derkach (21)
  5. Ahmet Dogan (20)
  6. Martin Tallman (18)

More People

Years
  1. 2025 (1)
  2. 2024 (2)
  3. 2023 (6)
  4. 2022 (6)
  5. 2021 (13)
  6. 2020 (8)

More Years

Publications
  1. Blood (21)
  2. Blood Advances (6)
  3. American Journal of Hematology (3)
  4. Leukemia and Lymphoma (3)
  5. Biology of Blood and Marrow Transplantation (2)
  6. Haematologica (2)

More Publications

Publishers
  1. American Society of Hematology (27)
  2. Elsevier Inc. (4)
  3. John Wiley & Sons, Inc. (3)
  4. Nature Publishing Group (3)
  5. Taylor & Francis Group (3)
  6. Elsevier Science, Inc. (2)

More Publishers

Results (53)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Molecular predictors and effectiveness of measurable residual disease (MRD) eradication with chemotherapy and allogeneic stem cell transplantation for acute myeloid leukemia
    Meeting Abstract

    Stahl, M.; Derkach, A.; Famulare, C.; Cho, C.; Devlin, S.; Farnoud, N.; Menghrajani, K.; Patel, M. A.; Cai, S. F.; Geyer, M. B.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma: final results from a clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Diamond, B.; Salcedo, M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in patients with multiple myeloma treated with continuous lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • High progression-free survival after intermediate intensity double unit cord blood transplantation in adults
    Journal Article

    Barker, J. N.; Devlin, S. M.; Naputo, K. A.; Skinner, K.; Maloy, M. A.; Flynn, L.; Anagnostou, T.; Avecilla, S. T.; Scaradavou, A.; Cho, C.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save
  • Stem cell mobilization and autograft minimal residual disease negativity with novel induction regimens in multiple myeloma
    Journal Article

    Bal, S.; Landau, H. J.; Shah, G. L.; Scordo, M.; Dahi, P.; Lahoud, O. B.; Hassoun, H.; Hultcrantz, M.; Korde, N.; Lendvai, N.; more...
    Biology of Blood and Marrow Transplantation (2020)

    Fulltext@MSK | Save
  • Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure
    Journal Article

    Ball, B. J.; Famulare, C. A.; Stein, E. M.; Tallman, M. S.; Derkach, A.; Roshal, M.; Gill, S. I.; Manning, B. M.; Koprivnikar, J.; McCloskey, J.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Mastey, D.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Plasmacytoid dendritic cell proportion is predictive of risk and outcomes in myelodysplastic syndromes
    Meeting Abstract

    Chan, A.; Zhang, Y.; Devlin, S. M.; Lewis, N.; Baik, J.; Arcila, M. E.; Klimek, V. M.; Roshal, M.; Xiao, W.
    Blood (2019)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Smith, E. L.; Shah, U. A.; Lu, S. X.; Mastey, D.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia
    Journal Article

    Xiao, W.; Goldberg, A. D.; Famulare, C. A.; Devlin, S. M.; Nguyen, N. T.; Sim, S.; Kabel, C. C.; Patel, M. A.; McGovern, E. M.; Patel, A.; more...
    Haematologica (2019)

    Fulltext@MSK | Save